Buch, Englisch, Band 216, 366 Seiten, Format (B × H): 183 mm x 260 mm, Gewicht: 908 g
Reihe: Neuromethods
Buch, Englisch, Band 216, 366 Seiten, Format (B × H): 183 mm x 260 mm, Gewicht: 908 g
Reihe: Neuromethods
ISBN: 978-1-0716-4231-3
Verlag: Springer US
This book explores the latest developments in the identification of biomarkers for early diagnosis of neurodegenerative diseases and methodologies for the biophysical; in vitro; cell-based; and in vivo profiling, during the early phases of drug discovery, new hits, leads, and drug candidates directed to a variety of biological targets with key pathogenic roles in neurodegenerative diseases. In the series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory.
Comprehensive and thorough, offers practical guidance to researchers in the medicinal chemistry community. The methods described in this book can be readily implemented in many laboratories and will aid new and experienced researchers with creating future treatments for these devastating diseases.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis.- BACE-1 Inhibition for the Treatment of Neurodegenerative Diseases: Rationale, Assay Methodologies, and Reference Compounds.- Identification of a-Synuclein Aggregation Inhibitors via High-Throughput Screening.- TDP-43 Modulation for the Treatment of Neurodegenerative Diseases: Rationale and Assay Methodologies.- Modulation of the KEAP1-NRF2 Pathway for the Treatment of Neurodegenerative Diseases: Rationale, Assay Methodologies, and Reference Compounds.- Monoamine Oxidase Inhibition for the Treatment of Neurodegenerative Diseases: Rationale, Assay Methodologies, and Reference Compounds.- Targeting Cannabinoid Receptors against Neurodegenerative Diseases: NanoLuc Binary Technology and Proximity Ligation In Situ Assay to Evaluate Pharmacological Activity of Novel Compounds and Receptors Heteromerization.- Cholinesterase Inhibition for the Treatment of Neurodegenerative Diseases: Assay Methodologies and Reference Compounds.- Use of Calcium-Sensitive Indicators for the Determination of NMDA Receptor Activity.- Cell-Based Assays to Assess Neuroprotective Activity.- Models of Neurodegenerative Diseases.- A Toolkit to Model Neurodegenerative Disease in Mouse Models of Alzheimer’s Disease.- Mouse Models of Amyotrophic Lateral Sclerosis.
